Sydney, Australia 3 May 2024
Highlights
- Eight abstracts have been accepted by the American Urological Association (AUA), American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meetings, showcasing the latest data from Clarity’s oncology portfolio.
- Abstracts of Clarity’s diagnostic clinical trials COBRA and CLARIFY were accepted for oral presentation at SNMMI and AUA Annual Meetings, respectively.
- Additional abstracts were accepted for the SECuRE, COBRA and CLARIFY trials at ASCO, and for the SECuRE, COMBAT and SABRE trials at SNMMI.
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that new data will be presented at the upcoming AUA, ASCO and SNMMI 2024 Annual Meetings, covering clinical results and trials in progress. The data showcases the extensive scope of Clarity’s Targeted Copper Theranostic (TCT) platform in developing multiple products for imaging and treating cancer patients, with focus on prostate cancer.
Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “The AUA, ASCO and SNMMI Annual Meetings are among the most prestigious conferences in urology, oncology and nuclear medicine, respectively. We are delighted that our data has been accepted for presentation at these world leading conferences. The abstracts accepted for presentations, including two oral presentations, highlight the exciting opportunities for our next-generation TCT radiopharmaceuticals as we continue to generate incredible data on what we strongly believe to be best in class assets for the treatment and diagnosis of cancer.
“We are looking forward to sharing this data as we continue to adhere to the highest standards of clinical research, work with world-class clinical sites and generate exciting results to date while expanding the platform into multiple indications. We are also looking forward to further developing our existing as well as novel TCT products as we get closer to our ultimate goal of improving treatment outcomes for children and adults with cancer.”
Data to be presented at 2024 AUA, ASCO and SNMMI Annual Meetings
| Product | Abstract Title | Conference |
| 64Cu-SAR-bisPSMA | CLARIFY: Positron Emission Tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy, a phase 3 diagnostic study | AUA – Oral presentation
Session Date Session Time Session Title |
| 64Cu-SAR-bisPSMA | COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy | ASCO – Poster presentation
Session Date Session Time Session Title/Track Sub Track Abstract # 5100 Poster Bd # 506 |
| 64Cu-SAR-bisPSMA | CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study) | ASCO – Poster presentation
Session Date Session Time Session Title/Track Sub Track Abstract # TPS5129 Poster Bd # 524a |
| 67Cu-SAR-bisPSMA | SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer
|
ASCO – Poster presentation
Session Date Session Time Session Title/Track Sub Track Abstract # TPS5116 Poster Bd # 517b |
| 64Cu-SAR-bisPSMA | COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy | SNMMI – Oral presentation
Session Date Session Time Session Title |
| 67Cu-SAR-bisPSMA | SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer | SNMMI – Poster presentation |
| 67Cu-SAR-BBN | COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate resistant prostate cancer ineligible for therapy with 177Lu-PSMA-617 | SNMMI – Poster presentation |
| 64Cu-SAR-BBN | SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in PSMA-negative biochemical recurrent prostate cancer patients | SNMMI – Poster presentation |
Posters and presentations containing study results will be available on Clarity’s official website after their presentation at the 2024 AUA, ASCO and SNMMI Annual Meetings: claritypharmaceuticals.com/pipeline/scientific_presentations
Abstracts for the 2024 ASCO Annual Meeting will be released on the 23rd of May at 5 PM ET and will be available at the conference website: conferences.asco.org/am/abstracts
About Clarity Pharmaceuticals
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
Media Contacts
Clarity Pharmaceuticals
Dr Alan Taylor
Executive Chairperson
+61 (0)413 871 165
ataylor@claritypharm.com
Citadel-MAGNUS
Catherine Strong
Investor/Media Relations
+61 (0)406 759 268
c.strong@morrowsodali.com
This announcement has been authorised for release by the Executive Chairperson.
